Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?

Authors


  • Potential conflict of interest: J.G. is a consultant/advisor for and received grants from Merck. He owns stock in Gilead. G.D. is a consultant/advisor and has received research grants from Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb, and AbbVie. He is on the speakers' bureau for Merck and Roche.

No abstract is available for this article.

Ancillary